Obermatt
See Similar Stocks →

Century Therapeutics

NAQ:IPSC · US15673T1007
BiotechnologySmall

360

45
Medium confidence — indicative
Profit price54
Cash yield1
Price/Sales84
Price/Book61
Return on Capital57
Cash Return on Capital64
Return on Equity56
Profit margins17

Cash truth not applicable for financial companies.

Sales growth1
Profit growth61
Reinvestment88
Price momentum82
Debt load45
Refinancing54
Debt Payback1
Liquidity73
Analyst ratings15
Opinion Changes96
Price Target Upside49
Market mood23
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Century Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2018
Employees98
Websitecenturytx.com
ISINUS15673T1007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesStem Cell TherapyGeneticsInflammationChronic DiseasesHematologyImmunologyOncologyBiotechnologyHealth CareHealth Diagnostics

Description

Century Therapeutics, Inc. operates as a biotechnology company. The company is harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabete…

Analysis

Middle-of-the-road

Century Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Century Therapeutics with its peers
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Fate Therapeutics
NMQ:FATE
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Celcuity
NAQ:CELC
96
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →